Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Wright Reports
|
$472.00
|
|
Provider: Datamonitor
|
$50.00
|
|
Provider: Datamonitor
|
$50.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Grindeks AS Opens Representative Office in Armenia
Grindeks AS announced that it is expanding its presence in the Commonwealth of Independent States countries and is opening a new representative office in Armenia. The representative office will cooperate with the national medicines authorities, wholesale and retail companies of pharmaceutical and medical products of Armenia, as well as will provide Grindeks AS medication registration and promotion. Grindeks AS began its activities in Armenia several years ago. The most demanded products of Grindeks AS in Armenia are Mildronate, Apilak-Grindeks, Karvidil, and Oxytocin-Grindeks.
Latest Developments for Grindeks AS
- Grindeks AS Confirms FY 2013 Turnover and Profit Guidance
- Grindeks AS Issues FY 2013 Turnover Guidance above Analysts’ Estimates; Issues FY 2013 Profit Guidance
- Grindeks AS Issues FY 2011 Revenue Guidance above I/B/E/S Estimates-SeeNews Nordic
- Grindeks AS Appoints Mr. Juris Bundulis as New Chairman of Management Board
Latest Key Developments in Pharmaceuticals
- Biogen Idec Inc And Swedish Orphan Biovitrum AB Presents New Data From Phase 3 Study Of Long-Lasting Hemophilia Factor Candidate ALPROLIX
- Medicines Co Announces Positive Results For Solo II Trial Of Oritavancin In Treatment Of Acute Bacterial Skin And Skin Structure Infections
- OHKI CO LTD Announces Concern of Uncollectible or Delayed Receivables
- CKD Bio Announces Resignation of Co-CEO
- Share this
- Link this
- Digg this


Follow Reuters